The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Hi MyIPA,
As well as the 7 Distributors signed up , add the UK = 8, see list below:-
Much to look forward too, during the upcoming weeks and months, as I see it!!:
. Riverfort have committed to providing an Equity Prepayment Facility of £5 million.
. News that RF have completely sold out All of their 6,500,000 shares
. Devote funding - £Value – ‘’ the total amount of funding to be made available under the programme will be determined in due course.’’
. ''and other aligned funding.''? !!
. As well as: In-kind contributions – Details
. Further AIHL Distributor sign ups - to those already in place covering Spain, France, Austria, Greece, Saudi Arabia, Kuwait and Turkey
. Update on the AIHL Test progress in the next 7 hospitals, with their expected up and running status.
. Notification of increased AIHL Test Sales in the UK.
. Further rollout of AHIL in the UK.
. Clearance/ regulatory approvals to sale our AIHL Test in various European Countries.
, News of rollout in Europe, and the rest of the World.
. Sales of our AIHL Test in Europe
. FDA Pre Sub Update - determining regulatory process, and requirements to place AIHL into the American market
. UKCA marking of our Genedrive CYP2C19 test
. NICE Final report, and Full validation of our CP2C19 stroke test
. Continued working with the NHS, and how this will be scheduled.
. Notification of further new Products.
. R&D Tax refund - £956,000 received in March 2023, and a further £500,000 due before Dec 31st 2023.
. Further £300,000 monthly drawdowns, over the next 8 months, plus RF warrant payments to our Genedrive, on RF exercise of those warrants. June warrants exercise payment equates to £168,000, and July warrants exercise payment equates to a further £168,000.
. Good Financial Position.
. Our SP rising.
All the above is IMHO !! DYOR.
Just to Clarify - the below Post is @starres:
What a Load of Bu*l Shi*e you Continually and Compulsively Post - since selling ''Totally Out'' of GDR (stated by You).
And now you say you are invested ''All In'' (I believe you said) into Burford Capital (Lon :Bur) - Yet you have Posted 51 Posts over the past 30 days - All Derogatory towards GDR - Not One Post on the 'Burford Capital' BB - You have become the Complete Troll, and even resort to Lie's - to support your claims.
The below are NOT ''Interim Results''
Audited Final Results
9 Nov 2021 07:00
RNS Number : 7206R
Audited Final Results
21 Nov 2022 07:00
RNS Number : 9816G
What a Load of Bu*l Shi*e you Continually and Compulsively Post - since selling ''Totally Out'' of GDR (stated by You).
And now you say you are invested ''All In'' (I believe you said) into Burford Capital (Lon :Bur) - Yet you have Posted 51 Posts over the past 30 days - All Derogatory towards GDR - Not One Post on the 'Burford Capital' BB - You have become the Complete Troll, and even resort to Lie's - to support your claims.
The below are NOT ''Interim Results''
Audited Final Results
9 Nov 2021 07:00
RNS Number : 7206R
Audited Final Results
21 Nov 2022 07:00
RNS Number : 9816G
LOL - Much to look forward too, during the upcoming weeks and months, as I see it!!:
. News that RF have completely sold out All of their 6,500,000 shares
. Devote funding - £Value – ‘’ the total amount of funding to be made available under the programme will be determined in due course.’’
. ''and other aligned funding.''? !!
. As well as: In-kind contributions – Details
. Further AIHL Distributor sign ups - to those already in place covering Spain, France, Austria, Greece, Saudi Arabia, Kuwait and Turkey
. Update on the AIHL Test progress in the next 7 hospitals, with their expected up and running status.
. Notification of increased AIHL Test Sales in the UK.
. Further rollout of AHIL in the UK.
. Clearance/ regulatory approvals to sale our AIHL Test in various European Countries.
, News of rollout in Europe, and the rest of the World.
. Sales of our AIHL Test in Europe
. FDA Pre Sub Update - determining regulatory process, and requirements to place AIHL into the American market
. UKCA marking of our Genedrive CYP2C19 test
. NICE Final report, and Full validation of our CP2C19 stroke test
. Continued working with the NHS, and how this will be scheduled.
. Notification of further new Products.
. R&D Tax refund - £956,000 received in March 2023, and a further £500,000 due before Dec 31st 2023.
. Further £300,000 monthly drawdowns, over the next 8 months, plus RF warrant payments to our Genedrive, on RF exercise of those warrants. June warrants exercise payment equates to £168,000, and July warrants exercise payment equates to a further £168,000.
. Good Financial Position.
. Our SP rising.
All the above is IMHO !! DYOR.
There was some decent size Buys yesterday amongst the 'what I believe were RF Selling':-
13-Jul-23 13:12:45 14.899 67,118 Buy* 14.80 14.90 10,000 O
13-Jul-23 13:10:34 14.899 67,118 Buy* 14.80 14.90 10,000 O
13-Jul-23 09:10:24 15.00 75,000 Buy* 14.50 15.00 11.25k
13-Jul-23 08:32:47 15.30 100,696 Buy* 14.50 15.50 15.41k
Agreed Choochie - It makes Perfect Sense !!!
Looks like RF are selling off the remainder of their 6.5 Mil shares in order to clear the path for Our GENEDRIVE to drawdown a further 300,000 shares in early August. RF will then take up a further allotment of Shares.
I am thinking they now have less than 1.5 Mil shares left?!!
My take is that RF believe they will make a fortune on their Warrant Shares when they exercise them at a Far Far Higher SP!!!
Hi gunto,
Agreed - why else would they put ''For Adults 10 strokes of the swab on the inside of each side of the cheek'' - If the Test was not intended for Adults.
I had clearly posted that 'It was ''My Understanding'' that the AIHL Test ''Can'' be used for Adults and Children - I did Not post that it ''was'' being used for Adults and Children at that time, as ''Incognito the False'' twisted his Post to say - For his Own Agenda??? LOL
Thanks for posting Gunto,
Interesting that the Video states for use on Neonates - 2 strokes of the Swab on the inside of each side of the cheek, and for Adults 10 strokes of the swab on the inside of each side of the cheek.
Looks like ''My Understanding'' from All the information I had read, and researched that the AIHL Test ''Can'' be used for Adults and Children as well as Neonates was not so far wrong afterall?!!
Much to look forward too, during the upcoming weeks and months, as I see it:
. Devote funding - £Value - – ‘’ the total amount of funding to be made available under the programme will be determined in due course.’’
. ''and other aligned funding.''? !!
. As well as: In-kind contributions – Details
. Further AIHL Distributor sign ups - to those already in place covering Spain, France, Austria, Greece, Saudi Arabia, Kuwait and Turkey
. Update on the AIHL Test progress in the next 7 hospitals, with their expected up and running status.
. Notification of increased AIHL Test Sales in the UK.
. Further rollout of AHIL in the UK.
. Clearance/ regulatory approvals to sale our AIHL Test in various European Countries.
. News of rollout in Europe, and the rest of the World.
. Sales of our AIHL Test in Europe
. FDA Pre Sub Update - determining regulatory process, and requirements to place AIHL into the American market
. UKCA marking of our Genedrive CYP2C19 test
. NICE Final report, and Full validation of our CP2C19 stroke test
. Continued working with the NHS, and how this will be scheduled.
. Notification of further new Products.
. R&D Tax refund - £956,000 received in March 2023, and a further £500,000 due before Dec 31st 2023.
. Further £300,000 monthly drawdowns, over the next 8 months, plus RF warrant payments to our Genedrive, on RF exercise of those warrants. June warrants exercise payment equates to £168,000, and July warrants exercise payment equates to a further £168,000.
. Good Financial Position.
. Our SP rising.
All the above is IMHO !! DYOR.
Much to look forward too, during the upcoming weeks and months, as I see it:
. Devote funding - £Value
. ''and other aligned funding.''? !!
. As well as: In-kind contributions – Details
. Further AIHL Distributor sign ups - to those already in place covering Spain, France, Austria, Greece, Saudi Arabia, Kuwait and Turkey
. Update on the AIHL Test progress in the next 7 hospitals, with their expected up and running status.
. Notification of increased AIHL Test Sales in the UK.
. Further rollout of AHIL in the UK.
. Clearance/ regulatory approvals to sale our AIHL Test in various European Countries.
. News of rollout in Europe, and the rest of the World.
. Sales of our AIHL Test in Europe
. FDA Pre Sub Update - determining regulatory process, and requirements to place AIHL into the American market
. UKCA marking of our Genedrive CYP2C19 test
. NICE Final report, and Full validation of our CP2C19 stroke test
. Continued working with the NHS, and how this will be scheduled.
. Notification of further new Products.
. R&D Tax refund - £956,000 received in March 2023, and a further £500,000 due before Dec 31st 2023.
. Further £300,000 monthly drawdowns, over the next 8 months, plus RF warrant payments to our Genedrive, on RF exercise of those warrants. June warrants exercise payment equates to £168,000, and July warrants exercise payment equates to a further £168,000.
. Good Financial Position.
. Our SP rising.
All the above is IMHO !! DYOR.
Hi MyIPA,
I had not seen the EMQN link until you posted it today - Thanks for posting.
I agree it does look like this is an easier, quicker and more cost effective route to take!!
It does appear that working/teaming with the UoM and the NHS brings so much to the table !!
From the RNS 31st March 2023 - RNS Number : 0323V
‘’Further, the Directors believe that a combination of the possibility of positive future news flow around the Company's two main assays as well as the potential for reasonable levels of liquidity in the Company's ordinary shares make the Facility the most attractive form of financing for the Company at the current time.’’
Much to look forward too, during the upcoming weeks and months, as I see it:
. Devote funding - £Value
. ''and other aligned funding.''? !!
. As well as: In-kind contributions – Details
. Further AIHL Distributor sign ups - to those already in place covering Spain, France, Austria, Greece, Saudi Arabia, Kuwait and Turkey
. Update on the AIHL Test progress in the next 7 hospitals, with their expected up and running status.
. Notification of increased AIHL Test Sales in the UK.
. Further rollout of AHIL in the UK.
. Clearance/ regulatory approvals to sale our AIHL Test in various European Countries.
, News of rollout in Europe, and the rest of the World.
. Sales of our AIHL Test in Europe
. FDA Update - determining regulatory process, and requirements to place AIHL into the American market
. UKCA marking of our Genedrive CYP2C19 test
. NICE Final report, and Full validation of our CP2C19 stroke test
. Continued working with the NHS, and how this will be scheduled.
. Notification of further new Products.
. R&D Tax refund - £956,000 received in March 2023, and a further £500,000 due before Dec 31st 2023.
. Further £300,000 monthly drawdowns, over the next 8 months, plus RF warrant payments to our Genedrive, on RF exercise of those warrants. June warrants exercise payment equates to £168,000, and July warrants exercise payment equates to a further £168,000.
. Good Financial Position.
. Our SP rising.
All the above is IMHO !! DYOR.
agreed johnlay****,
the uom and nhs partners will dish out the funds, and this money will go the development costs of products such as our cyp2c19 - obviously not directly into our bank account.
however, this funding is more about the money that will not be coming out of our genedrives bank account, due to development costs that will not be coming out of our bank account!!!! - could be massive savings to our outgoing costs!!!
Looking forward to the DEVOTE funding announcement!!
We know that we spend circa £125,000 per product development per month, and we usually have two products in development at any one time.
So it will be interesting to see whether DEVOTE Funding will now cover the same level of our current development costing/products going forward?!!
If they do then I take it that means we will not need to fork out the £250,000 of Development costs each month - which in turn could reduce our Monthly running costs from £400,000 per month to £150,000 per month? - now that would have a Great Positive Impact on our financial position?!!
We also know that 'Sales of our AIHL Test are going on in the Background' - Looking forward to hearing how well the Quantity is Growing?!!
Well this is how I see our position anyway !!
The above is all -- IMHO
Nathan91 - what an ABSOLUTE IDIOT:-
Posting his Dross on several stocks:-
Nathan91
Posted in: COPL
Posts: 69
Price: 2.65
No Opinion
P&DToday 13:07
⚠️word of warning for newbies⚠️
Sell before the Day traders Dumping today!
Don't left holding the BABY!
Nathan91
Posted in: GDR
Posts: 69
Price: 17.25
No Opinion
RE: DEVOTE confirmation of fundingToday 13:06
⚠️word of warning for newbies⚠️
Sell before the Day traders Dumping today!
Don't left holding the BABY!
Nathan91
Posted in: RCGH
Posts: 69
Price: 87.50
No Opinion
P&DToday 12:39
⚠️word of warning for newbies⚠️
Sell before the Day traders Dumping today!
Don't left holding the BABY!
Nathan91
Posted in: GDR
Posts: 69
Price: 17.25
No Opinion
RE: Genedrive to rocket to 36p this monthToday 12:18
Massive sell off going now. Don't left holding the BABY!
The Truth is Our GDR SP is UP:-
Market Summary >
Genedrive PLC
17.59 GBX
+0.090 (0.51%)today
3 Jul, 13:14 BST
# Trades 26
Vol. Sold 93,333
Sold Value £15.92k
Vol. Bought 113,360
Bought Value £19.91k